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The incidence of prostate carcinoma is very low in Eastern
countries, such as Japan, suggesting that life style conditions
may play a crucial role in the development of this pathology.
Dietary -6 polyunsaturated fatty acids, such as linoleic (LA)
and arachidonic (AA) acids, have been shown to stimulate
the proliferation of prostate cancer cells after being con-
verted into 5-HETE by means of the 5-lipoxygenase (5-LOX)
pathway. Blockade of 5-LOX activity has been proposed as an
attractive target for the prevention of the mitogenic action
of dietary fats on prostate cancer. The 5-LOX gene has been
shown to carry a response element for the orphan nuclear
receptor ROR (for its ROR1 isoform in particular) in its
promoter region. We attempt to clarify whether activation
of ROR might modulate the expression of 5-LOX, thus
interfering with the mitogenic activity of fatty acids in pros-
tate cancer cells. We show that in androgen-independent DU
145 prostate cancer cells, LA, AA and their metabolite
5-HETE exert a strong stimulatory action on cell prolifera-
tion. This effect is completely counteracted by the simulta-
neous treatment of the cells with a non redox inhibitor of
5-LOX activity. We then demonstrate that: i) ROR, and
speciﬁcally its ROR1 isoform, is expressed in DU 145 cells;
ii) activation of ROR, by means of the thiazolidinedione
derivative CGP 52608 (the synthetic ROR activator), signif-
icantly reduces 5-LOX expression, both at mRNA (as evalu-
ated by comparative RT-PCR) and at protein (as investigated
by Western blot analysis) level (this was conﬁrmed by the
reduced activity of 5-LOX in CGP 52608 treated cells); and
iii) the treatment of DU 145 cells with CGP 52608 completely
abrogated the proliferative action of both LA and AA. These
results have been conﬁrmed in another androgen-indepen-
dent prostate cancer cell line (PC3). Our data indicate that,
by decreasing the expression of 5-LOX, activation of ROR
might interfere with the mitogenic activity of fatty acids on
prostate cancer. We have shown previously that CGP 52608
reduces the proliferation and the metastatic behavior of DU
145 cells. These observations indicate that the orphan nu-
clear receptor ROR might be considered as a molecular
target for the development of new chemopreventive or che-
motherapeutic strategies for prostate carcinoma.
© 2004 Wiley-Liss, Inc.
Key words: prostate cancer; ROR; 5-lipoxygenase; linoleic acid;
arachidonic acid
Prostate cancer incidence is particularly high in the United
States and Europe and much lower in Japan and in other Asian
countries.1 In addition to circulating levels of androgens, environ-
mental factors, such as dietary fats, have been suggested to be
responsible for this difference.2–4 Among polyunsaturated fatty
acids, the -6 acids that are present in animal fat and in vegetable
oils, have been shown to enhance the risk of prostate cancer
occurrence. On the contrary, -3 acids, that can be found in high
amounts in ﬁsh oils, seem to exert a protective action against the
growth of the tumor.5–7
Linoleic acid (LA), a member of the -6 polyunsaturated fatty
acid family, is converted to arachidonic acid (AA), which is then
incorporated into the phospholipids of the cell membrane. Arachi-
donic acid is in turn metabolized to the series of eicosanoids after
having been released from phospholipids by PLA2.8,9 Eicosanoids
have been reported to mediate the mitogenic activity of both LA
and AA on different tumor cell lines.5,10–14
In prostate cancer, AA has been shown to stimulate cell prolif-
eration mainly through its conversion to 5-HETE (5-hydroxyeico-
satetraenoic acid), via the 5-lipoxygenase (5-LOX) pathway.15–17
Moreover, 5-LOX has been reported recently to be overexpressed
in prostate carcinoma.18 Taken together, these observations led to
the suggestion that 5-LOX might be considered as an attractive
target for the development of new chemopreventive or chemother-
apeutic strategies.
ROR is a transcription factor belonging to the family of orphan
nuclear receptors, for which currently endogenous ligands are
unknown.19,20 The gene for the human ROR receptor encodes at
least 4 distinct isoforms: ROR 1, 2, 3, and 4 (also named
RZR).21,22 The 4 splicing variants share common DNA- and
putative ligand-binding domains, but possess distinct amino-ter-
minal domains.22 ROR receptors bind preferentially to response
elements (ROREs) composed of a typical hexameric core-binding
site RGGTCA (R  A or G), and an A/T rich 5-ﬂanking se-
quence.21,22 By binding to ROREs in the promoter region of target
genes, ROR has been shown to be involved in the control of
several physiological processes, such as cerebellar develop-
ment,23,24 muscle cell differentiation,25 bone metabolism26 and
immune functions.27
A RORE sequence has also been identiﬁed in the promoter
region of the human 5-LOX gene. In particular, this RORE spe-
ciﬁcally binds ROR1 and RZR, but not ROR2 and 3.28 Our
experiments attempt to verify whether in prostate cancer cells, the
activation of ROR might interfere with the mitogenic action of
fatty acids through the modulation of 5-LOX expression. We used
the thiazolidinedione derivative CGP 52608, which has been
shown previously to activate the nuclear receptor.29,30
MATERIAL AND METHODS
Materials
The thiazolidinedione derivative CGP 52608 (1-[3-allyl-4-oxo-
thiazolidine-2-ylidene]-4-methyl-thisemicarbazone) was kindly
donated by Dr. D. Evans (Novartis, Basel, Switzerland). This
compound has been demonstrated previously to activate the or-
phan nuclear receptor ROR.29,30 Linoleic acid (LA), arachidonic
acid (AA), 5-hydroxyeicosatetraenoic acid (5[S]-HETE and 5[R]-
HETE) and delipidized bovine serum albumin (BSA) were pur-
chased from Sigma Chemical (St. Louis, MO). MK886, the inhib-
itor of 5-lipoxygenase activating protein (FLAP), was obtained
from Merck Frosst (Quebec, Canada).
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Cell culture
The human androgen-independent DU 145 and PC3 prostate
cancer cell lines were obtained from American Type Culture
Collection (Rockville, MD). Cells were routinely grown in RPMI-
1640 medium (Seromed Biochrom, Berlin, Germany) supple-
mented with 5% fetal bovine serum (FBS) (Gibco, Paisley, Scot-
land, UK), glutamine (1 mM) and antibiotics (100 U/ml penicillin
G sodium, 100 g/ml streptomycin sulphate) in a humidiﬁed
atmosphere of 5% CO2/95% air.
Cell proliferation studies
Effects of fatty acids and 5-HETEs on cell proliferation.To study
the effects of fatty acids and 5-HETEs on cell proliferation, DU
145 cells were plated at a density of 2  104 cells/plate in
RPMI-1640 supplemented with 5% FBS. Forty-eight hours after
plating, the medium was changed to RPMI-1640 supplemented
with 0.5% FBS and delipidized BSA (5 M). Cells were then
treated with LA (108–105 M), AA (108–106 M), 5(S)-HETE
or 5(R)-HETE (5  108–106 M) for 7 days. Fatty acids and
5-HETEs were pre-complexed with lipid-free BSA before addition
to the medium. Final concentration of BSA was maintained at 5
M throughout the experiments. Control cells were treated with
the 0.5% FBS additioned medium containing BSA only. At the end
of the treatment, cells were harvested and counted by hemocytom-
eter.
To conﬁrm the role of 5-LOX in the growth modulatory activity
of fatty acids, DU 145 cells were treated, for 7 days, with AA
(107 M), either in the absence or in the presence of the 5-LOX
inhibitor MK886 (107–105 M). Among the biochemical inhib-
itors of 5-LOX, this compound has been shown to act by interact-
ing with FLAP and interfering with the presentation of AA to
5-LOX enzyme at the nuclear envelope membrane.31
Effects of ROR activation on the mitogenic activity of fatty
acids.DU 145 cells were treated as described above, either with
LA (106 M) or AA (107 M) in the absence or in the presence of
CGP 52608 (107 M). Cells were harvested and counted after 7
days of treatment. All the cell proliferation experiments were
repeated at least 3 times. Five plates/dose were included in each
experiment.
RT-PCR for the ROR isoforms
The speciﬁc isoform of the ROR receptor that might be ex-
pressed in DU 145 cells was investigated by RT-PCR. After
phenol-chloroform extraction, 1 g of total RNA from cancer cells
was used in a reverse transcription reaction. The same RNA has
been used in all the RT-PCR reactions. cDNA synthesis was
carried out using the Gene AMP kit (Perkin Elmer Cetus, Norwalk,
CT), with an oligo(dT)16 as a primer for the reverse transcriptase.
Samples containing cDNAs were then ampliﬁed in a 100 l
solution containing PCR buffer (50 mM KCl, 10 mM Tris-HCl), 2
mM MgCl2, 15 pmol of a pair of speciﬁc primers and 2.5 U Taq
Polymerase. Thirty-ﬁve cycles of ampliﬁcation were carried out in
a programmable heat block (Perkin Elmer Cetus) (1-min denatur-
ation at 94°C, 45-sec primer annealing at 60°C and 2-min primer
extension at 72°C). The sense primers were: 5-AAACATG-
GAGTCAGCTCCG-3 for ROR1; 5-CTCCAAATACTCCAT-
CAGTGTATCC-3 for ROR2; 5-CAACTTGAGCACATA-
AACTGG-3 for ROR3; 5-TGTATTTTGTGATCGCAGAG-3
for ROR4. For all the isoforms, the antisense primer used was:
5-CATACAAGCTGTCTCTCTGC-3.28 The same RT-PCR con-
ditions were used to amplify 	-actin cDNA; in this case the
primers used were 5-TGACGGGGTCACCCACACTGTGC-
CCATCTA-3 (sense) and 5-CTAGAAGCATTTGCGGTGGAC-
GATGGAGGG-3 (antisense).32 After RT-PCR, the ampliﬁed
DNA products were separated on a 1.5% agarose gel and stained
with ethidium bromide.
Immunoprecipitation and western blot analysis for ROR1
To conﬁrm the expression of the ROR1 isoform at the protein
level, DU 145 cells were harvested and solubilized in RIPA buffer
(50 mM Tris-HCl, pH 7.7), 150 mM Na3VO4, 50 mM NaF, 0.3
mM phenylmethylsulfonylﬂuoride and 5 mM iodoacetic acid.
ROR has been immunoprecipitated with 10 g/10 l of a poly-
clonal antibody against the ROR1 receptor (sc-6062, Santa Cruz
Biotechnology, Santa Cruz, CA) and electrophoresed on 10%
polyacrylamide gel under reducing conditions. Precipitated pro-
teins were transferred onto a nitrocellulose ﬁlter, which was then
probed with the sc-6062 antibody for 2 hr at room temperature.
Filters were then incubated for 1 hr at room temperature with an
anti-goat IgG (1:10.000). Antibody bound to ROR1 was detected
using the Supersignal detection system (Celbio, Pierce, Rockford,
IL) after a 5–10-min exposure to a Hyperﬁlm X-ray ﬁlm (Amer-
sham Pharmacia Biotech, Milano, Italy) at room temperature.
RT-PCR for 5-LOX expression
In preliminary experiments, RT-PCR was carried out to choose
the adequate number of cycles for ampliﬁcation of 5-LOX and
	-actin (as an internal control) cDNAs. To this purpose, RNA (1
g) from DU 145 cells was reverse transcribed and cDNAs were
ampliﬁed by PCR as described above. The primers used for 5-LOX
were: 5-CACTGACGACTACATCTACC-3 (sense) and 5-GT-
TCCACTCCATCCATCGAT-3 (antisense);28 the primers for
	-actin were the same as described above.32 PCR reactions con-
sisted of 1-min denaturation at 94°C, 30-sec annealing at 60°C and
2-min primer extension at 72°C. The number of cycles carried out
were 30–45 for 5-LOX and 15–30 for 	-actin cDNAs, respec-
tively. After RT-PCR, the ampliﬁed cDNAs were separated on an
agarose gel, stained with ethidium bromide and photographed
under UV light.
To study the effects of ROR activation on the expression of
5-LOX, DU 145 cells were plated in 100 mm-dishes at a density
of 8  105 cells/dish. Twenty-four hours after plating, the media
were changed to experimental media (RPMI-1640 supplemented
with 5% FBS) either in the absence or in the presence of CGP
52608 (107 M) for 6, 12, 24, 36, 48 and 60 hr. At the end of the
treatment, cells were harvested and RNAs were extracted and
submitted to RT-PCR at adequate cycles. Equal RT reaction so-
lutions were utilized in PCR reaction in the presence of the speciﬁc
primers for 5-LOX and for 	-actin.
Western blot analysis of 5-LOX
To study the effects of ROR activation on the level of 5-LOX
protein, DU 145 cells were plated at a density of 8x104 cells/plate.
Twenty-four hours later, the media were changed to experimental
media and cells were treated daily with CGP 52608 (107 M) for
4 days (96 hr). At the end of the treatment, cells were harvested
and protein fractions were prepared as described for the ROR
protein. Proteins were electrophoresed and transferred onto a ni-
trocellulose ﬁlter. Filters were probed with the rabbit polyclonal
5-LOX antibody (LO32) (kindly provided by Dr. R.N. Young,
Merk Frosst) for 2 hr at room temperature. Filters were then
incubated for 1 hr at room temperature with an anti-rabbit IgG
(1:10,000; Santa Cruz Biotechnology, Santa Cruz, CA). Antibody
bound to 5-LOX was detected using the Supersignal detection
system, as described for the ROR protein.
Evaluation of 5-LOX enzymatic activity
5-LOX activity was evaluated after the formation of 5(S)-HETE
upon incubation of DU 145 cells with AA and the calcium iono-
phore A23187, after a daily treatment, for 4 days (96 hr), with CGP
52608 (107 M) or with its vehicle. Brieﬂy, cells were washed and
incubated with 1 ml of PBS containing 1 M of AA and the
calcium ionophore A23187 (2 M) for 5 min at 37°C. After
centrifugation at 12,000g, 4°C for 5 min, supernatants were loaded
onto a solid phase extraction cartridge (1 ml OASIS, Waters,
Milford, MA), preactivated with 1 ml methanol and 1 ml of water.
Arachidonic acid metabolites were eluted using 1 ml of methanol/
acetonitrile (50/50, v:v) and taken to dryness using a SpeedVac
Rotary Evaporator (Savant, Farmingdale, NY). After reconstitu-
tion in 200 l of HPLC mobile phase (see below) samples were
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injected into a Beckman Liquid Chromatograph mod 110B (Beck-
man Analytical, Palo Alto, CA). Separation of mono-HETEs was
carried out on Ultrasphere ODS column (4.6  250 mm, 5 m,
Beckman Analytical) eluted isocratically at 1 ml/min using a
mobile phase of acetonitrile:water:acetic acid 60:40:0.01, pH 5
with ammonium hydroxide. UV absorbance was monitored at 236
nm with a Beckman diode-array UV Detector and full scans
(220–300 nm) were acquired every 2 sec. Retention time of
mono-HETEs was determined using synthetic 5(S)-HETE and
15(S)-HETE.
Experiments in PC3 cells
Experiments were carried out in PC3 cells, to conﬁrm the effects
of ROR activation on the proliferative action of fatty acids in a
second experimental model of prostate cancer cells. In preliminary
studies, PC3 cells were treated with CGP 52608 (1011–106 M),
to conﬁrm the antiproliferative effects of the thiazolidinedione
derivative on androgen-independent prostate cancer cells, as pre-
viously reported for DU 145 cells.33 PC3 cells were then treated
with AA (108 M–5 106 M), harvested and counted after 7
days of treatment. Finally, PC3 cells were treated with AA (5 
106 M), either in the absence or in the presence of CGP52608
(107 M) (as described for DU 145 cells) and counted after 7 days
of treatment.
Statistical analysis
Data from cell proliferation studies were analyzed according to
the Dunnett’s test after one-way analysis of variance.34
RESULTS
Effects of fatty acids and 5-HETE on DU 145 cell proliferation
Figure 1a shows that LA signiﬁcantly stimulates cell prolifera-
tion in the range of doses 5  107–5  106 M. AA exerted its
mitogenic action on DU 145 cells at the concentrations of 5 
107 M and 107 M (Fig. 1b). Finally, 5(S)-HETE induced a
signiﬁcant increase of cell growth when used at the dose of 5 
107 M (Fig 1c). 5(R)-HETE did not modify DU 145 cell prolif-
eration at any dose used (data not shown). DU 145 cells were then
treated with AA (107 M) either in the absence or in the presence
of the 5-LOX inhibitor MK886 (107–105 M). Figure 2 shows
that MK886 counteracts the stimulatory action of AA on prostate
cancer cells in a dose-dependent way, being signiﬁcantly effective
at 5  106 and 106 M. These results conﬁrm the proliferative
effect of fatty acids on prostate cancer cells and the crucial role
played by 5-LOX in this activity.
Expression of the ROR1 isoform in DU 145 cells
The 5-LOX gene carries a ROR1 response element on its
promoter region.28 We have shown previously that the ROR
family is expressed in DU 145 prostate cancer cells.33 Experiments
have now been carried out to identify the speciﬁc isoform of the
orphan nuclear receptor that might be present in these cells. By
RT-PCR, we have observed that only one cDNA band, corre-
sponding to the ROR1 cDNA, was present in DU 145 cells (Fig.
3a, upper panel, lane 1). No band corresponding to ROR2, 3, or
4 cDNAs could be obtained (Fig. 3a, upper panel, lanes 2–4).
	-Actin cDNAs were ampliﬁed in all the 4 samples, indicating that
RNA was not degraded (Fig. 3a, lower panel, lanes 1–4). To
conﬁrm the expression of ROR1 in prostate cancer cells, the
receptor was ﬁrst immunoprecipitated and then submitted to gel
electrophoresis and to Western blot analysis. As shown in Figure
3b, a major protein band with molecular weight of about 80 kDa,
recognizing the sc-6062 antibody (Santa Cruz Biotechnology), was
present in DU 145 cells. These results indicate that ROR1 is the
major isoform of the receptor to be expressed in these cells.
Effects of ROR activation on 5-LOX expression
Because the 5-LOX gene carries a RORE in its promoter region,
we reasoned that the activation of the nuclear receptor might affect
the expression of the enzyme. We veriﬁed this hypothesis both at
the mRNA (comparative RT-PCR analysis) and at the protein
(Western blot analysis) level.
RT-PCR analysis.In preliminary experiments, we carried out
RT-PCR analysis at various cycles to choose the adequate
number of cycles for the detection of the mRNA expression of
5-LOX and of 	-actin (as an internal standard) mRNA expres-
sion. The intensity of each band increased in parallel with the
increasing number of PCR cycles (data not shown). We con-
cluded that the adequate number of cycles was 35 for 5-LOX
and 20 for 	-actin.
To study the effects of ROR activation on the expression of
5-LOX, DU 145 cells were treated with the thiazolidinedione
derivative CGP 52608 (107 M), the exogenous ROR ligand and
activator,29,30 and RNA was extracted at different time intervals
(from 6–60 hr) for comparative RT-PCR. As shown in Figure 4,
in control DU 145 cells, changing of the medium at the beginning
of the experiments induces an increase of the expression of 5-LOX
mRNA at 36, 48 and 60 hr. It is well known that FBS contains fatty
acids and these have been shown to increase the expression of the
FIGURE 1 – Effects of linoleic acid (LA) (a), arachidonic acid (AA)
(b), and 5(S)-hydroxyeicosatetraenoic acid, 5(S)-HETE (c) on DU 145
cell proliferation. Each experiment was repeated 3 times with identical
results. Data are expressed as the mean cell number/plate 
 SEM.
*p  0.05 vs. controls (C).
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enzyme.15–17 Treatment of the cells with CGP 52608 completely
counteracted the increase at all the time intervals (Fig. 4). As
expected, the level of expression of 	-actin was not modiﬁed either
in controls or in treated cells at any time interval considered
(Fig. 4).
Western blot analysis.The effects of ROR activation on the
level of the 5-LOX protein were evaluated at 96 hr after the
treatment of DU 145 cells with the thiazolidinedione derivative
(107 M), by using a speciﬁc antibody against the enzyme. As
shown in Figure 5, the treatment resulted in a decreased level of
expression of the protein, when compared to that found in un-
treated controls. Treatment with CGP 52608 for shorter time
intervals did not induce any signiﬁcant variation in 5-LOX levels
(data not shown). From these results, it seems that the decrease of
5-LOX levels at the protein level is more pronounced than that
observed at the mRNA level. It must be underlined, however, that
for the RT-PCR experiments the cells received only one treatment
at the beginning of the observation period. Cells were treated daily
for 4 days for the Western blot analysis.
Effects of ROR activation on 5-LOX enzymatic activity
Incubation of DU 145 cells with AA in the presence of the
calcium ionophore A23187 resulted in the formation of 5(S)-
HETE, as assessed by retention time using isocratic RP-HPLC
separation (Fig. 6a,b) and UV spectral analysis (Fig. 6b, inset).
Treatment of cells with CGP 52608 (107 M), the exogenous
ROR ligand and activator, showed a marked decrease (68 
 6%,
mean 
 SD) of the peak corresponding to 5(S)-HETE (Fig. 6c),
supporting the hypothesis that 5-LOX mRNA, protein and activity
are all downregulated by ROR activation.
Effects of ROR activation on the mitogenic activity of fatty
acids
Because fatty acids are mitogenic on prostate cancer cells
through their conversion into 5-HETE by 5-LOX activity, and
because ROR activation signiﬁcantly reduces 5-LOX expression
in DU 145 cells, we reasoned that CGP 52608 might counteract the
proliferative action of fatty acids on these cells. DU 145 cells were
FIGURE 2 – Effects of the 5-LOX inhibitor MK 886 on the stimula-
tory activity of AA (107 M) on DU 145 cell proliferation. Each
experiment was repeated 3 times with identical results. Data are
expressed as the mean cell number/plate 
 SEM. *p  0.05 vs.
controls (C); **p  0.05 vs. AA.
FIGURE 3 – Expression of the different ROR isoforms in DU 145
cells. (a) RT-PCR analysis of the different isoforms of ROR and of
	-actin. (Upper panel) Ethidium bromide-stained gel of the ampliﬁed
cDNAs obtained in the presence of oligonucleotide primers speciﬁc
for ROR1 (lane 1), ROR2 (lane 2), ROR3 (lane 3), and ROR4
(lane 4). (Lane 5) RT-PCR control. (Lower panel) Ethidium bromide-
stained gel of the ampliﬁed cDNAs obtained in the presence of
oligonucleotide primers speciﬁc for 	-actin. (b) Western blot analysis
of ROR after immunoprecipitation using the sc-6062 antibody.
FIGURE 4 – Effects of CGP 52608 on 5-LOX mRNA expression in
DU 145 cells. Cells were treated with CGP 52608 (107 M); at the
indicated time intervals, total RNA was extracted and analyzed by
RT-PCR at the appropriate cycles, as described in Material and Meth-
ods, for 5-LOX and 	-actin. One representative of 3 experiments is
reported.
FIGURE 5 – Effects of CGP 52608 on 5-LOX protein expression in
DU 145 cells. Cells were treated daily, for 4 days (96 hr), with CGP
52608 (107 M); protein extracts were then prepared and submitted to
Western blot analysis, as described in Material and Methods. One
representative of 3 experiments is reported. Lane 1, controls; lane 2,
CGP 52608.
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treated with LA (106 M) or AA (107 M), either in the absence
or in the presence of CGP 52608 (107 M). As expected, we found
that CGP 52608 completely counteracts the stimulatory effect of
both LA (Fig. 7a) and AA (Fig. 7b).
Experiments in PC3 cells
In preliminary experiments we have shown that the ROR1
isoform of the nuclear receptor is expressed in PC3 cells, both at
mRNA and at protein levels (data not shown). The treatment of
PC3 cells with CGP 52608 dose-dependently inhibited PC3 cell
proliferation, as previously described by our group for DU 145
cells (Fig. 8a).33 AA stimulated PC3 cell growth, although at a
higher dose (5  106 M) than that required to increase DU 145
cell proliferation (Fig. 8b). This dose corresponds to that previ-
ously reported by other authors to be required for AA to maximally
stimulate PC3 cell growth.15
Finally, PC3 cells were treated with AA (5 106 M), either in
the absence or in the presence of CGP 52608 (107 M). The
thiazolidinedione derivative completely counteracted the stimula-
tory effect of AA (Fig. 8c), conﬁrming the results obtained in DU
145 cells.
DISCUSSION
Dietary fatty acids, and in particular -6 polyunsaturated fatty
acids, are associated with an increased risk of the tumor of the
prostate.7 Our data supports this observation by showing that both
LA and AA exert a signiﬁcant proliferative effect on prostate
cancer cells. This is in line with those data reported previously on
PC3 cells, as well as on LNCaP androgen-dependent prostate
cancer cells.5,15 At variance with our data, Rose and Connolly5 did
not observe any effect of LA on DU 145 cell growth. At the
FIGURE 6 – Effects of CGP 52608 on 5-LOX enzymatic activity in
DU 145 cells. Cells were treated daily, for 4 days (96 hr) with CGP
52608 (107 M); then, they were washed and incubated with AA (1
M) and A23187 (2 M) for 5 min at 37°C. Supernatants were
analyzed by RP-HPLC as described in Material and Methods. (a)
Chromatographic tracing of UV absorbance at 236 nm from standard
15(S)-HETE and 5(S)-HETE. (b) Chromatographic tracing of UV
absorbance at 236 nm from control DU 145 cells; inset shows the full
UV spectrum of chromatographic peak eluting at the retention time of
standard 5(S)-HETE. (c) Chromatographic tracing of UV absorbance
at 236 nm from DU 145 cells treated with CGP 52608 (107 M) for 96
hr.
FIGURE 7 – Effects of CGP 52608 (107 M) on the stimulatory
activity of LA (106 M) (a) and of AA (107 M) (b) on DU 145 cell
proliferation. Each experiment was repeated 3 times with identical
results. Data are expressed as the mean cell number/plate 
 SEM.
*p  0.05 vs. controls (c); **p  0.05 vs. LA (a) or AA (b).
91ROR, 5-LOX AND FATTY ACIDS IN PROSTATE CANCER
moment, the reason for this discrepancy is not clear; however it
might be related to methodological differences (e.g., cell culture
conditions, length of the treatment, etc.) present in the 2 studies.
Our results, together with previous reports15–17 also conﬁrm
that both LA and AA, to exert their mitogenic effect, need to be
metabolized through the 5-lipoxygenase pathway. Therefore,
modulation of 5-lipoxygenase expression or activity has been
suggested as a possible target for the development of new
chemopreventive or chemotherapeutic strategies for prostate
cancer.17
We have stated that the promoter region of 5-LOX contains
a response element for the orphan nuclear receptor ROR1,28,35
suggesting that the expression of the enzyme might also be
regulated through the activation of the nuclear receptor. We
have shown that this speciﬁc isoform of the receptor is ex-
pressed in DU 145 cells, both at the mRNA and at the protein
level. We have demonstrated that 5-LOX expression is induced
by FBS additioned medium; it is actually well known that FBS
contains fatty acids and these have been shown to increase the
expression of the enzyme.15–17 The activation of ROR signif-
icantly counteracted this overexpression, both at the mRNA and
at protein level. In line with these results, the treatment with the
thiazolidinedione derivative markedly decreased 5-LOX enzy-
matic activity, as shown by the decreased production of 5(S)-
HETE observed in DU 145 cells exposed to exogenous AA in
the presence of the calcium ionophore A23187. These data
indicate that in the presence of serum, and therefore in the case
of high supply of fatty acids, the activation of the orphan
nuclear receptor ROR signiﬁcantly decreases the overexpres-
sion of 5-LOX and, consequently, its activity.
On the basis of these observations, we reasoned that the thia-
zolidinedione derivative CGP 52608, through the reduction of the
expression and of the activity of 5-LOX, might affect the prolif-
erative effects of -6 polyunsaturated fatty acids on prostate
cancer cells. We veriﬁed this hypothesis by showing that, in DU
145 cells, the mitogenic activity of both LA and AA can be
completely counteracted by the simultaneous treatment of the cells
with the thiazolidinedione derivative. These results have been
further conﬁrmed in another androgen-independent prostate cancer
cell line (PC3).
So far, only inhibitors of 5-LOX activity or compounds that
reduce the association of the enzyme with arachidonic acid and
FLAP31,36 have been proposed as effective agents to inhibit fatty
acid-induced cancer cell proliferation.5,11,15–17,37 Our data indicate
that ROR1 activating compounds might be considered as possi-
ble antagonists of the mitogenic activity of fatty acids on prostate
cancer because of their ability to inhibit the 5-lipoxygenase ex-
pression.
In previous studies, we have shown that the activation of the
orphan nuclear receptor ROR reduces the proliferation of DU
145 cells, both in vitro and in vivo, through the modulation of the
expression of cell cycle-related genes (p21WAF1/CIP1, cyclin A).34
Moreover, CGP 52608 also decreases the metastatic behavior of
DU 145 cells by affecting the expression of cell adhesion mole-
cules.38 These observations indicate that the activation of this
receptor might counteract cancer growth through complementary
and additive mechanisms: antiproliferative, antimetastatic and an-
tagonistic toward the mitogenic effect of dietary fatty acids. There-
fore, ROR might be considered as a possible molecular target for
the development of new, and hopefully successful, strategies for
prostate cancer chemoprevention or chemotherapy. It is interesting
to underline that thiazolidinedione derivatives, such as CGP
52608, by modulating ROR activity, have also been shown to
possess strong antiinﬂammatory and immunostimulatory activi-
ties.27,29,30
In 1995, Wiesenberg et al.35 indicated melatonin as the possible
endogenous ligand for ROR; however, this observation remained
controversial. More recently, while analyzing the crystal structure
of the ligand binding domain of ROR, Kallen et al.39 have
identiﬁed cholesterol as the possible endogenous ligand for the
nuclear receptor. If conﬁrmed, this ﬁnding will certainly improve
the understanding of the multiple biological functions of this
transcription factor.
The molecular mechanisms through which ROR and speciﬁ-
cally the ROR1 isoform, might regulate the expression of 5-LOX
are still unknown. It has been shown that the nuclear receptor can
interact with either coactivators or corepressors. It has been then
proposed that ROR1 can assume 2 different conformations: an
active state that promotes binding to coactivator complexes, and a
repressive state that allows the interaction with corepressor com-
plexes.40 Very recently, it has been shown that ROR1 induces
Rev-erb gene expression.41 Rev-erb, in turn, is known to inter-
FIGURE 8 – Effects of CGP 52608 (1011–106 M) alone (a), of AA
(108–5  106 M) alone (b), and of CGP 52608 (107 M) either
alone or in the presence of AA (5  106 M) (c) on PC3 cell
proliferation. Each experiment was repeated 3 times with identical
results. Data are expressed as the mean cell number/plate 
 SEM.
*p  0.05 vs. controls (c); **p  0.05 vs. AA.
92 MORETTI ET AL.
act with the nuclear receptor corepressor N-CoR.42,43 It is then
possible that in prostate cancer cells the activated ROR1 might
also reclute speciﬁc corepressors to inhibit the expression of the
5-LOX gene.
Our data indicate that activation of the orphan nuclear receptor
ROR1, which is expressed in prostate cancer cells, decreases the
expression of 5-LOX enzyme thus counteracting the mitogenic
action of -6 polyunsaturated fatty acids on these cells.
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